UAE Inhibitor TAK-243 Clinical Trials
2 recruitingDrug
Phase 12
Showing 1–2 of 2 trials
Recruiting
Phase 1
Studying TAK-243 in Patients With Advanced Cancer
Advanced Malignant Solid NeoplasmAdvanced Lymphoma
National Cancer Institute (NCI)95 enrolled1 locationNCT06223542
Recruiting
Phase 1
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Recurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+4 more
National Cancer Institute (NCI)42 enrolled5 locationsNCT03816319